James Miskin

2.5k total citations · 1 hit paper
30 papers, 1.5k citations indexed

About

James Miskin is a scholar working on Molecular Biology, Genetics and Ecology, Evolution, Behavior and Systematics. According to data from OpenAlex, James Miskin has authored 30 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 15 papers in Genetics and 6 papers in Ecology, Evolution, Behavior and Systematics. Recurrent topics in James Miskin's work include Virus-based gene therapy research (15 papers), Viral Infectious Diseases and Gene Expression in Insects (9 papers) and Vector-Borne Animal Diseases (6 papers). James Miskin is often cited by papers focused on Virus-based gene therapy research (15 papers), Viral Infectious Diseases and Gene Expression in Insects (9 papers) and Vector-Borne Animal Diseases (6 papers). James Miskin collaborates with scholars based in United Kingdom, United States and Switzerland. James Miskin's co-authors include Christopher Hunt Keir, Bruce L. Levine, Keith Wonnacott, Linda K. Dixon, Charles C. Abrams, Lynnette C. Goatley, Kyriacos Mitrophanous, Ignacio Rodríguez‐Crespo, José M. Escribano and Covadonga Alonso and has published in prestigious journals such as Science, Nucleic Acids Research and PLoS ONE.

In The Last Decade

James Miskin

30 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Global Manufacturing of CAR T Cell Therapy

2017 537 citations Bruce L. Levine, James Miskin et al. Molecular Therapy — Methods & Clinical Development profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James Miskin United Kingdom	17	793	515	433	265	260	30	1.5k
Carl Hay United States	16	669 0.8×	501 1.0×	451 1.0×	265 1.0×	352 1.4×	22	1.9k
Clayton W. Beard United States	20	911 1.1×	271 0.5×	389 0.9×	274 1.0×	359 1.4×	30	1.6k
Yiming Xie United States	24	943 1.2×	175 0.3×	510 1.2×	69 0.3×	400 1.5×	49	1.7k
Michelle Donnelly United Kingdom	9	847 1.1×	120 0.2×	309 0.7×	136 0.5×	197 0.8×	10	1.4k
Garry A. Luke United Kingdom	9	858 1.1×	115 0.2×	279 0.6×	131 0.5×	167 0.6×	16	1.4k
Lorraine E. Hughes United Kingdom	8	979 1.2×	126 0.2×	314 0.7×	123 0.5×	161 0.6×	9	1.5k
Takashi Ohashi Japan	27	620 0.8×	233 0.5×	276 0.6×	665 2.5×	1.2k 4.5×	70	2.3k
Yuji Sunden Japan	21	443 0.6×	297 0.6×	89 0.2×	158 0.6×	317 1.2×	86	1.5k
Alik Honigman Israel	25	918 1.2×	166 0.3×	370 0.9×	39 0.1×	384 1.5×	59	1.8k
Pablo de Felipe United Kingdom	17	966 1.2×	106 0.2×	416 1.0×	77 0.3×	142 0.5×	27	1.4k

Countries citing papers authored by James Miskin

Since Specialization

Citations

This map shows the geographic impact of James Miskin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Miskin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Miskin more than expected).

Fields of papers citing papers by James Miskin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Miskin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Miskin. The network helps show where James Miskin may publish in the future.

Co-authorship network of co-authors of James Miskin

This figure shows the co-authorship network connecting the top 25 collaborators of James Miskin. A scholar is included among the top collaborators of James Miskin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Miskin. James Miskin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Farley, David, et al.. (2025). Risks of replication-competent retro/lentivirus from associated vector systems: Is it time for a roadmap toward reduced testing?. Molecular Therapy — Methods & Clinical Development. 33(4). 101601–101601. 1 indexed citations

Williams, Thomas J., et al.. (2024). Auto‐transduction in lentiviral vector bioprocessing: A quantitative assessment and a novel inhibition strategy. Biotechnology and Bioengineering. 121(12). 3728–3741. 3 indexed citations

Davies, Lee, et al.. (2024). Lentiviral vector determinants of anion‐exchange chromatography elution heterogeneity. Biotechnology and Bioengineering. 121(9). 2936–2951. 6 indexed citations

Davies, Lee, et al.. (2024). Degradation of specific glycosaminoglycans improves transfection efficiency and vector production in transient lentiviral vector manufacturing processes. Frontiers in Bioengineering and Biotechnology. 12. 1409203–1409203. 1 indexed citations

Price, E.H., Felix Feyertag, Thomas G. Evans, et al.. (2024). What is the real value of omics data? Enhancing research outcomes and securing long-term data excellence. Nucleic Acids Research. 52(20). 12130–12140. 8 indexed citations

Williams, Thomas J., et al.. (2024). Development of novel lipoplex formulation methodologies to improve large-scale transient transfection for lentiviral vector manufacture. Molecular Therapy — Methods & Clinical Development. 32(2). 101260–101260. 6 indexed citations

Levine, Bruce L., James Miskin, Keith Wonnacott, & Christopher Hunt Keir. (2017). Global Manufacturing of CAR T Cell Therapy. Molecular Therapy — Methods & Clinical Development. 4. 92–101. 537 indexed citations breakdown →

Thorne, Barbara A., Christopher J. Nicolai, D. J. Campbell, et al.. (2015). Development of a replication-competent lentivirus assay for dendritic cell-targeting lentiviral vectors. Molecular Therapy — Methods & Clinical Development. 2. 15017–15017. 7 indexed citations

Zallocchi, Marisa, Katie Binley, Yatish Lad, et al.. (2014). EIAV-Based Retinal Gene Therapy in the shaker1 Mouse Model for Usher Syndrome Type 1B: Development of UshStat. PLoS ONE. 9(4). e94272–e94272. 83 indexed citations

10.

MacLachlan, Timothy K., et al.. (2013). Not Reinventing the Wheel: Applying the 3Rs Concepts to Viral Vector Gene Therapy Biodistribution Studies. PubMed. 24(1). 1–4. 4 indexed citations

11.

Binley, Katie, Peter Widdowson, Michelle Kelleher, et al.. (2012). Safety and Biodistribution of an Equine Infectious Anemia Virus-Based Gene Therapy, RetinoStat ^® , for Age-Related Macular Degeneration. Human Gene Therapy. 23(9). 980–991. 48 indexed citations

12.

Miskin, James, et al.. (2012). Development of an Equine-Tropic Replication-Competent Lentivirus Assay for Equine Infectious Anemia Virus-Based Lentiviral Vectors. Human Gene Therapy Methods. 23(5). 309–323. 2 indexed citations

13.

Jarraya, Béchir, Sabrina Boulet, G. Ralph, et al.. (2009). Dopamine Gene Therapy for Parkinson’s Disease in a Nonhuman Primate Without Associated Dyskinesia. Science Translational Medicine. 1(2). 2ra4–2ra4. 133 indexed citations

14.

Iqball, Sharifah, et al.. (2007). Factors that influence VSV‐G pseudotyping and transduction efficiency of lentiviral vectors—in vitro and in vivo implications. The Journal of Gene Medicine. 9(5). 345–356. 29 indexed citations

15.

Vink, Conrad A., Sheena Lee, Peter Treasure, et al.. (2006). The integration profile of EIAV-based vectors. Molecular Therapy. 14(4). 536–545. 35 indexed citations

16.

Siapati, Elena K., Brian Bigger, James Miskin, et al.. (2005). Comparison of HIV- and EIAV-Based Vectors on Their Efficiency in Transducing Murine and Human Hematopoietic Repopulating Cells. Molecular Therapy. 12(3). 537–546. 27 indexed citations

17.

Miskin, James, et al.. (2005). A replication competent lentivirus (RCL) assay for equine infectious anaemia virus (EIAV)-based lentiviral vectors. Gene Therapy. 13(3). 196–205. 18 indexed citations

18.

Goatley, Lynnette C., et al.. (2004). The CD2v protein of African swine fever virus interacts with the actin-binding adaptor protein SH3P7. Journal of General Virology. 85(1). 119–130. 50 indexed citations

19.

Bulimo, Wallace, James Miskin, & Linda K. Dixon. (2000). An ARID family protein binds to the African swine fever virus encoded ubiquitin conjugating enzyme, UBCv1. FEBS Letters. 471(1). 17–22. 20 indexed citations

20.

Miskin, James, Angela Farrell, W.J. Cunliffe, & Keith T. Holland. (1997). Propionibacterium acnes, a resident of lipid-rich human skin, produces a 33 kDa extracellular lipase encoded by gehA. Microbiology. 143(5). 1745–1755. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact